The QMSR's Hidden ROI: LATAM's Device Trial Advantage

By Julio G. Martinez-Clark, CEO, bioaccess

On February 2, 2026, the FDA's new Quality Management System Regulation (QMSR) took effect, replacing the legacy Quality System Regulation (QSR) under 21 CFR Part 820. The QMSR incorporates ISO 13485:2016, the international standard for medical device quality management systems (QMS), by reference, aligning the FDA's manufacturing quality framework with the standard already used by regulators worldwide.¹ This is the most significant shift in U.S. medical device quality requirements in nearly three decades.²

Every device company is scrambling to comply. Dozens of articles explain what to change in a QMS. But nobody is writing about what the QMSR enables — and that is the real story.

When the FDA aligned Part 820 with ISO 13485, it quietly created a harmonized quality framework between the United States and Latin America, where device regulators such as ANVISA (Brazil), INVIMA (Colombia), and COFEPRIS (Mexico) already require ISO 13485 for medical device manufacturing and clinical investigations.² For the first time, device performance data generated at ISO 13485-certified sites in Latin America sits on the same QMS foundation that the FDA now mandates domestically — strengthening the case for FDA acceptance of international device data at significantly lower cost and faster timelines.^3,4

As someone who manages first-in-human (FIH) and early feasibility studies (EFS) across Latin America with data used in investigational device exemption (IDE), 510(k), De Novo, and premarket approval (PMA) submissions, I see this firsthand every week. Here is what device sponsors need to understand.

The Compliance Trap: Everyone Sees The Burden, Nobody Sees The Unlock

The QMSR conversation has been dominated by a single narrative: compliance burden. What documentation must change? How will FDA inspections differ? What are the transition risks?

These are legitimate concerns, and the final rule — issued January 31, 2024 — gives manufacturers a clear road map.⁵ But this compliance-centric framing misses a strategic opportunity hiding in plain sight. The QMSR did not merely update a regulatory requirement. It eliminated the foundational quality gap between the U.S. device framework and the international regulatory infrastructure that already governs clinical investigations in Latin America.

Prior to the QMSR, a device sponsor conducting an early feasibility study in Colombia or Brazil operated under a dual-QMS reality: the clinical site maintained ISO 13485 compliance as required by the local regulator, while the sponsor's U.S. manufacturing operations followed the QSR — a framework that, despite its alignment in intent, differed meaningfully from ISO 13485 in structure, terminology, and documentation requirements. This misalignment created friction during FDA submissions. Reviewers could question whether overseas clinical data was generated under a quality system truly equivalent to U.S. manufacturing standards.

The QMSR closes that gap. When both the U.S. sponsor and the Latin American clinical site operate under the same ISO 13485 framework, the quality system narrative in an FDA submission becomes seamless.

LATAM's ISO 13485 Infrastructure: Already Built

The compliance infrastructure in Latin America is more mature than most U.S.-based regulatory affairs directors realize. Brazil's National Health Surveillance Agency (ANVISA) now fully aligns its GMP inspection requirements with ISO 13485. International manufacturers seeking Class III and IV device registration in Brazil are expected to hold Medical Device Single Audit Program (MDSAP) certification.⁶ MDSAP allows a single regulatory audit to satisfy the requirements of multiple authorities simultaneously — including the FDA, ANVISA, Health Canada, Japan's PMDA, and Australia's TGA.⁷

Colombia's INVIMA requires ISO 13485 certification for manufacturers of medical devices entering the Colombian market, and the agency has been progressively strengthening its alignment with international standards.⁸ Mexico's COFEPRIS, which introduced an abbreviated regulatory pathway in September 2025, allowing manufacturers to leverage FDA approvals for registration in as few as 30 days, similarly recognizes ISO 13485 as part of its quality framework.⁶

The practical implication is significant: clinical investigation sites across Latin America already operate under the same QMS standard the FDA now mandates. This is not an aspiration or a transition plan. For ISO 13485-certified sites across the region, it is the current operating reality.²^,6

The MDSAP Bridge: From Audit Efficiency To Data Credibility

The Medical Device Single Audit Program deserves particular attention in the post-QMSR landscape.⁷ MDSAP was designed to reduce audit redundancy for manufacturers selling into multiple regulated markets. But its strategic value extends far beyond administrative efficiency. When a device manufacturer holds MDSAP certification, it demonstrates to the FDA that its quality system has been audited against the requirements of all five participating regulatory authorities — including Brazil, where clinical investigations are frequently conducted.

Post-QMSR, this creates a powerful evidentiary bridge: the manufacturer's QMS, the MDSAP audit results, and the Latin American clinical site's ISO 13485 certification all speak the same quality language.

For device sponsors planning IDE submissions or building clinical evidence packages for 510(k), De Novo, or PMA pathways, this alignment is not theoretical. It directly addresses one of the most common FDA review questions about international clinical data: Was this data generated under an adequate quality system?¹⁰ The MDSAP audit report now provides a documented third-party-verified answer.

The Cost Equation: Why This Matters Operationally

The quality harmonization story would be merely academic if Latin America did not also offer compelling operational advantages for device clinical investigations.

Furthermore, sites in Latin America have consistently demonstrated superior recruitment performance metrics compared to those in North America for industry-sponsored Phase 3 trials, leading to accelerated enrollment and overall development timelines.⁴ Specifically, Brazil has been cited for its faster recruitment rates, higher patient retention, and lower overall costs compared to the U.S. and Europe, establishing a clear competitive edge for device trials.⁴

The region achieves per-patient costs 25 to 35 percent lower than those in equivalent studies conducted in the United States.^3,4,11 Clinical timelines can be 40 percent faster due to streamlined regulatory pathways and efficient site activation processes.^3,4 The patient populations across Latin America are ethnically diverse, which strengthens the generalizability of clinical evidence for global regulatory submissions.

The strategic deployment of regulatory reliance frameworks, such as Mexico's abbreviated pathway for devices with prior FDA approval, translates regulatory efficiency into operational speed, accelerating time to market. Additionally, the vast and ethnically diverse patient populations across countries like Mexico and Argentina further support high enrollment rates, surpassing those seen in North American trials.

Prior to the QMSR, sponsors who leveraged these advantages still had to manage the narrative around quality system differences. Every FDA submission using Latin American clinical data required careful framing of why the data was trustworthy despite being generated under a different QMS framework.

That defensive posture is no longer necessary. The QMSR has aligned the underlying quality infrastructure, allowing sponsors to present Latin American clinical evidence on its merits — faster enrollment, lower costs, diverse populations — without the QMS caveat.

A Framework For Sponsors: Leveraging QMSR Alignment

Device sponsors looking to capitalize on the QMSR's hidden ROI should consider the following strategic framework.

First, audit your MDSAP status. If your organization does not hold MDSAP certification, the post-QMSR environment makes the business case stronger than ever. MDSAP certification demonstrates harmonized quality compliance across the FDA and ANVISA simultaneously, creating a documented bridge between your U.S. operations and Latin American clinical sites.

Second, evaluate the Latin American clinical sites' ISO 13485 certification status. Not all sites are equal. Prioritize clinical investigation sites that hold current ISO 13485 certification from an accredited registrar and can demonstrate active compliance through recent audit reports.

Third, integrate the quality narrative into your regulatory strategy from the start. Do not treat Latin American clinical data as supplementary evidence that requires defensive positioning. In the post-QMSR environment, data from ISO 13485-certified sites in Latin America carries the same quality system foundation as data generated domestically. Structure your IDE, 510(k), or PMA submission accordingly.

Fourth, engage regulatory consultants who understand both the QMSR requirements and the Latin American regulatory landscape. The intersection of U.S. and LATAM device regulation is a specialized domain, and generic compliance advice will not capture the strategic opportunity that the QMSR has created.

Looking Forward: The Harmonization Dividend

The QMSR's alignment with ISO 13485 is part of a broader global harmonization trend. The International Medical Device Regulators Forum (IMDRF) continues to drive convergence across regulatory frameworks.¹² MDSAP affiliate members — including Argentina, South Korea, Israel, Mexico, South Africa, and Taiwan — signal expanding recognition of harmonized quality standards.⁵

For medical device manufacturers, this means the strategic value of QMSR alignment with Latin America will only grow. As more regulators adopt ISO 13485 as the common quality language, clinical evidence generated under this framework becomes more portable across markets. The companies that recognize the QMSR as more than a compliance exercise — and instead see it as a strategic unlock for international clinical evidence — will be the ones that build competitive advantages in device development speed, cost efficiency, and regulatory success.

The QMSR compliance deadline has passed. The question now is not whether your QMS meets the new standard. It is whether you are leveraging what that standard makes possible.

References:.

1. U.S. Food and Drug Administration. (2026, February 2). Quality Management System Regulation (QMSR). https://www.fda.gov/medical-devices/postmarket-requirements-devices/quality-management-system-regulation-qmsr
2. Emergo by UL. Brazil GMP (B-GMP) Quality System Compliance. https://www.emergobyul.com/services/brazil-gmp-b-gmp-quality-system-compliance
3. Clinical Leader. (2022, July 5). Latin America's Landscape for Medtech Clinical Trials. https://www.clinicalleader.com/doc/latin-america-s-landscape-for-medtech-clinical-trials-0001
4. Martinez-Clark, J. (2025, July 10). Brazil's Competitive Edge: Infrastructure and Operational Advantages for Medical Device Trials. Med Device Online. https://www.meddeviceonline.com/doc/brazil-s-competitive-edge-infrastructure-and-operational-advantages-for-medical-device-trials-0001
5. Morgan Lewis. (2024, October 10). February 2, 2026 Is Quickly Approaching - Are You QMSR Ready? https://www.morganlewis.com/pubs/2024/10/february-2-2026-is-quickly-approaching-are-you-qmsr-ready
6. MedDeviceGuide. (2026, April 5). LATAM Medical Device Registration Comparison Guide. https://meddeviceguide.com/blog/latam-medical-device-registration-comparison-guide
7. U.S. Food and Drug Administration. Medical Device Single Audit Program (MDSAP). https://www.fda.gov/medical-devices/cdrh-international-affairs/medical-device-single-audit-program-mdsap
8. MedDeviceGuide. (2026, April 5). Colombia INVIMA Medical Device Registration Guide. https://meddeviceguide.com/blog/colombia-invima-medical-device-registration-guide
9. Pure Global. (2025, August 6). Mexico's COFEPRIS 2025 Abbreviated Pathway for Medical Devices. https://pureglobal.com/blog/mexicos-cofepris-2025-abbreviated-pathway-for-medical-devices
10. U.S. Food and Drug Administration. (2023, October 8). Acceptance of Clinical Data to Support Medical Device Applications and Submissions. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acceptance-clinical-data-support-medical-device-applications-and-submissions
11. L.E.K. Consulting. (2025, August 12). Unlocking Brazil's Clinical Trial Opportunity: A Strategic Roadmap. https://www.lek.com/insights/life-sciences-pharma/unlocking-brazils-clinical-trial-opportunity-strategic-roadmap
12. International Medical Device Regulators Forum (IMDRF). https://www.imdrf.org

About The Author:

Julio G. Martinez-Clark is co-founder and CEO of bioaccess, a market access consultancy that works with medical device companies to help them do early-feasibility clinical trials and commercialize their innovations in Latin America. Julio is also the host of the Global Trial Accelerators podcast. He has a bachelor's degree in electronics engineering (BSEE) and a master's degree in business administration (MBA).